Completing the 3,000 pages of procedures for microbiological and chemical testing analysis, as well as related supporting documents, furthers A5’s goal of establishing its contract research unit.
The documents provide a blue print to guide A5’s scientific and regulatory procedures in support of its interferon-based products group and CRO clients.
"Completion of our SOP documentation is a significant milestone for the establishment of our world class CRO division. I am very pleased that our team was able to complete this task ahead of schedule", said Richard Azani, president and CEO of A5.